SCHEMBL365433

SCHEMBL365433

CS(=O)(=O)NC(=O)c1ccccc1C#N

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
MYC P01106 1/20 0.51
LMNA P02545 3/20 0.49
PPIA P62937 1/20 0.46
KAT6A Q92794 1/20 0.45
ALDH1A1 P00352 2/20 0.43
PTPRG P23470 1/20 0.41
HTT P42858 2/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PLA2G7 Q13093 1/20 0.39
OPRK1 P41145 1/20 0.39
SCN9A Q15858 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38666347 0.80 NPC1 (0.55) MYCLMNAALDH1A1PTPRGKDM4E
SCHEMBL2728048 0.79 POLB (0.67) POLBLMNAPPIAKAT6AALDH1A1
SCHEMBL21906758 0.75 PPIA (0.50) POLBLMNAPPIAKAT6AALDH1A1
SCHEMBL6970508 0.75 PPIA (0.50) POLBLMNAPPIAKAT6AALDH1A1
SCHEMBL181067 0.75 ALDH1A1 (0.55) POLBMYCLMNAALDH1A1KDM4E
SCHEMBL28113677 0.75 PPIA (0.50) POLBLMNAPPIAKAT6AALDH1A1
SCHEMBL6654274 0.75 MYC (0.61) POLBMYCKAT6AALDH1A1HTT
SCHEMBL20324936 0.75 ALDH1A1 (0.69) POLBLMNAPPIAALDH1A1HTT
SCHEMBL679379 0.74 SCN9A (0.56) SCN9A
SCHEMBL7985045 0.74 MYC (0.55) POLBMYCALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007883-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A POLB 4438/4885MYC 3393/4885LMNA 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.